TABLE 2

Concentrations of lascufloxacin in plasma, epithelial lining fluid, and alveolar macrophages, and site-to-plasma concentration ratiosa

Time (h) of samplingConcn (μg/ml)Site-to-plasma concn ratio
CpCELFCAMCELF/CpCELF/CfpbCAM/CpCAM/Cfpb
10.576 ± 0.14512.3 ± 3.7419.9 ± 16.522.4 ± 9.0586.4 ± 35.031.9 ± 20.3123 ± 77.8
20.501 ± 0.08769.22 ± 3.459.13 ± 5.7618.4 ± 5.6870.9 ± 21.918.5 ± 12.071.0 ± 46.0
40.443 ± 0.04197.15 ± 3.219.68 ± 3.0416.5 ± 7.5663.6 ± 29.221.9 ± 6.7584.3 ± 25.9
60.387 ± 0.01195.84 ± 1.7221.8 ± 17.215.2 ± 4.7458.3 ± 18.356.4 ± 43.7217 ± 167
240.176 ± 0.05452.65 ± 0.8806.03 ± 2.8815.0 ± 2.3857.5 ± 9.3038.0 ± 22.6146 ± 87.2
  • a Abbreviations: Cp, CELF, and CAM, concentrations of lascufloxacin in plasma, epithelial lining fluid (ELF), and alveolar macrophages (AM), respectively; Cfp, free concentration of lascufloxacin in plasma. Data are means and SD for six subjects.

  • b The free fraction of lascufloxacin in plasma is assumed to be 0.26.